

Venue:

Auditorium, The Black Diamond, The Royal Library, Copenhagen

Organising Committee:

Dr. Oscar Della Pasqua, Clinical Pharmacology & Discovery Medicine, GSK, UK

Dr. Lars Erichsen, Experimental Medicine, Ferring Pharmaceuticals A/S, Denmark

Dr. Kim Kristensen, Clinical Pharmacology Medical Science, Astra Zeneca, Sweden

4th Satellite Symposium

**Predictive Modelling
in Drug Development**



This Satellite Symposium is jointly sponsored by AstraZeneca, Ferring & GlaxoSmithKline

12 June 2007

Copenhagen Denmark



Predictive Modelling in Drug Development

Dear Colleague,

It is an honour for us to invite you to Copenhagen, Denmark, for the 4th Satellite Symposium on "Predictive Modelling in Drug Development".

Predictive modelling and simulation can optimise the drug development programme and support the rationale for drug labelling. AstraZeneca, Ferring and GSK are committed to creating additional opportunities to share views about a major challenge in pharmaceutical R&D, i.e., the ability to generate information with predictive value. We hope you will join us in the scientific discussion on the future of intelligent drug development.

The Organising Committee

Programme

I - Modelling & Simulation from lead optimisation to candidate selection

- 13.00 - 13.30 [Modelling systems biology](#)
Dr Jesper Tegnér
IFM Computational Biology, Linköping University, Sweden
- 13.30 - 14.00 [Biosimulation](#)
Prof Erik Mosekilde
Dept of Physics, Technical University of Denmark, Denmark
- 14.00 -14.20 [Whole-body PBPK modelling in drug research and discovery](#)
Dr Stefan Willmann
Bayer Technology Services GmbH, Germany

II - Modelling & Simulation from First time in man to Phase II

- 14.20 - 14.40 [Reverse-engineering the POC - Bayesian adaptive PK/PD studies](#)
Dr Daren Austin
Clinical Pharmacology & Discovery Medicine, GlaxoSmithKline, UK
- 14.40 - 15.00 [Coffee break](#)
- 15.00 -15.20 [Dose selection in prostate cancer treatment with a GnRH antagonist](#)
Dr Lars Erichsen
Ferring Pharmaceuticals, Denmark

III - Modelling & Simulation from Full Development to Product Line Extension

- 15.20 - 15.40 [Can Bayes prevent QTc prolongation? A challenge beyond random effects](#)
Dr Kevin Krudys
Clinical Pharmacology & Discovery Medicine, GlaxoSmithKline, UK
- 15.40 - 16.00 [An application of clinical utility functions in Phase III](#)
Dr Marie Cullberg
Clinical Pharmacology, AstraZeneca, Sweden

- 16.00 - 16.20 [Tea Break](#)

IV - Keynote Lecture

- 16.20 - 17.30 [Evidence synthesis and the expected value of research in drug development.](#)
Prof Tony Ades & Prof Karl Claxton
University of Bristol & University of York, United Kingdom
- 17.30 - 18.00 [Reception](#)